ArticleBMC pulmonary medicine2025
MSCs regulate oxidative stress through the Nrf2 pathway to treat chronic obstructive pulmonary disease.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Secretome Derived From Serum-Free Media of SHED-MSCs Can Modulate THP-1-Derived Macrophage Cells.Journal of cellular and molecular medicine · 2026Article
- Activation of Nrf2 with natural flavonoids and mesenchymal stromal/stem cells: mechanisms and therapeutic potential for inflammatory diseases.Stem cell research & therapy · 2026Review
- Therapeutic effects and potential targets of UC-MSC-Exo in a mouse model of COPD.Scientific reports · 2026Article
- Emerging targeted therapies for chronic obstructive pulmonary disease: from symptom control to precision medicine.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChronic obstructive pulmonary disease (COPD) has become a great public health concern. While existing treatments can provide relief from COPD, they do not cure the disease. Stem cell transplantation is an emerging treatment modality that may play an important role in COPD treatment.
methodsA COPD model was constructed by exposing mice to tobacco smoke and administering bacterial lipopolysaccharide via intranasal drops. The progression of COPD was monitored after the transplantation of MSCs, and oxidative stress-related pathways were evaluated to explore the relationship among COPD, oxidative stress and stem cell transplantation. HE staining and Masson's trichrome staining were used to detect pulmonary lesions and the degree of pulmonary fibrosis. The levels of oxidative stress-related molecules were evaluated via qRT‒PCR and ELISA. Nrf2 pathway molecule expression was detected by immunofluorescence.
resultsCompared with the control group, we successfully established a tobacco smoke-induced COPD model with an increased lung macrophage number, inflammatory cell infiltration, enlarged alveoli, and pulmonary fibrosis. After MSC transplantation, the oxidative stress level was reduced, and the lung condition improved, 4-HNE in COPD mice decreased by 90pg/mg prot, IL-6 decreased by 15.55pg/ml, ROS decreased by 1.9 × 10
conclusionThis study confirmed the therapeutic effect of transplanted MSCs on tobacco- and lipopolysaccharide-induced COPD and revealed that MSCs ameliorate COPD by regulating oxidative stress-related pathways. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.